investors in today’s “pure” cannabis companies.
On the pharmaceutical side, we believe “Big Pharma” will own the important CBD drug therapies. They simply have wider reach and an ability to address a global market; therefore, we expect any company that develops a “hit” CBD drug to quickly become the target of an acquisition.
With edible legalization coming in December and other CPG items, such as beverages, hitting the shelves this year, what should investors be looking out for? How are you preparing for this next wave of legalization in Canada?
It’s very exciting to see how this plays out in the fall. We’re trying to find the companies that can execute on bringing products to market first and establishing a brand. Ultimately, it’s the development of the customer that matters most. We think there’s a strong first-mover advantage. That being said, we don’t know which formats will be the most successful so we are paying close attention.
We have not even touched on the animal care sector. How big do you think this could be?
This is a great example of the seemingly endless possibilities for products derived from cannabis. Pet care is a massive industry and popular product trends can drive meaningful demand. This could become a meaningful product line for companies looking to diversify their businesses.
215